Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar

Rocket Pharmaceuticals detailed a defined path to completing its FDA-aligned pivotal Phase 2 trial of RP-A501 in Danon disease: 12 male patients at a recalibrated dose, with success requiring at least 7 patients to meet co-primary endpoints at 12 months, supporting a potential accelerated approval pathway. The first three patients treated under the modified protocol completed initial observation without clinical or laboratory evidence of thrombotic microangiopathy or capillary leak syndrome -- the safety issues that prompted dose recalibration after a fatal adverse reaction at the original dose. Longer-term Phase 1 follow-up showed sustained biological activity, with all six patients demonstrating LAMP2 expression and at least 10% left ventricular mass index reduction at ~12 months and durable biomarker reductions out to three to seven years. Rocket expects to complete pivotal dosing by mid-2027 with topline results anticipated mid-2028; it models a U.S. Danon population of roughly 10,000-11,000 including 4,000 males.

•25d ago

Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital

Hercules Capital (HTGC) has agreed to provide Rocket Pharmaceuticals a credit facility of up to $150 million, with $35 million funded at closing. The deal is staged: a $35M optional draw, a $30M tranche tied to a Danon disease clinical milestone, and a $50M tranche pending Hercules' investment committee approval, with a 30-month interest-only period and 48-month maturity plus warrants. For HTGC, this is a routine life-sciences venture-debt origination that deploys capital into a commercial-stage biotech borrower; Rocket's cash runway extends into Q3 2028, potentially 2029 with additional draws.

•26d ago

Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease

Rocket Pharmaceuticals announced alignment with the FDA on completing the pivotal Phase 2 trial of RP-A501 in Danon disease, with the agency confirming a 12-patient pivotal efficacy population and continued enrollment at the recalibrated dose. Initial safety data from the first three patients showed no clinical or laboratory evidence of thrombotic microangiopathy or capillary leak syndrome, and all three count toward the pivotal population. Nine additional patients remain to be dosed, with completion expected by mid-2027. The FDA preserved the established 12-month co-primary endpoints — myocardial LAMP2 protein expression and a 10% reduction from baseline in left ventricular mass index — which are intended to support a potential accelerated approval. Management will host a comprehensive Danon disease program webinar on October 6, 2026, at 4:30 p.m. ET.

•1mo ago

Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress

Rocket reported Q2 2026 net income of $123.2 million, or $1.08 per diluted share, driven by the $180 million sale of a Priority Review Voucher. The transaction boosted cash reserves to $283.7 million, extending the company’s projected runway into the second quarter of 2028 and funding the advancement of its cardiovascular pipeline. Clinically, the company confirmed no significant safety concerns in the initial three Danon disease patients dosed with RP-A501, and it continues to prepare for the commercial launch of KRESLADI in the fourth quarter.

•2mo ago

Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease

Rocket Pharmaceuticals reported positive safety data from the first three Danon disease patients treated with RP-A501 under a modified Phase 2 protocol. The updated regimen, featuring a recalibrated dose of 3.8 × 10¹³ GC/kg and a refined immunomodulatory strategy, showed no signs of thrombotic microangiopathy (TMA) or capillary leak syndrome. Management is engaging with the FDA to align on dosing the remaining patients in the 12-patient pivotal study, with a regulatory pathway update expected in the second half of 2026.

•2mo ago

Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million

Rocket Pharmaceuticals closed the sale of its Rare Pediatric Disease Priority Review Voucher for gross proceeds of $180 million. The voucher was granted by the FDA in March 2026 following the approval of KRESLADI, the company’s gene therapy for severe leukocyte adhesion deficiency-I. The non-dilutive proceeds increase pro forma cash to approximately $322.6 million, extending the company’s operational runway into the second quarter of 2028.

•4mo ago

Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress

Rocket Pharmaceuticals reported a Q1 2026 net loss of $47.6 million, or $0.42 per share, with operating expenses decreasing year-over-year due to disciplined resource allocation. The company strengthened its balance sheet with the $180 million non-dilutive monetization of its Rare Pediatric Disease Priority Review Voucher, resulting in a pro forma cash position of approximately $322.6 million. This cash position is expected to fund operations into the second quarter of 2028, providing stability as it reinitiates dosing in the pivotal Phase 2 trial of RP-A501 for Danon disease. Additionally, Rocket anticipates first patient dosing in the Phase 1 study of RP-A701 for BAG3-related dilated cardiomyopathy by mid-2026.

•5mo ago

Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher

Rocket Pharmaceuticals sold its Rare Pediatric Disease Priority Review Voucher for $180 million in non-dilutive capital. The transaction extends the company's cash runway into the second quarter of 2028, significantly de-risking its financial position. Proceeds will be allocated to advancing the cardiovascular gene therapy pipeline, including programs for Danon disease, PKP2-ACM, and BAG3-DCM.

•6mo ago